Changes in Hong Kong stocks | Xinwei Medical-B (06609) rose more than 10%, adjusted profit is expected to double in the first half of the year, and continued breakthroughs in core business

The Zhitong Finance App learned that Xinwei Medical-B (06609) rose by more than 10%. As of press release, it had risen 10.38% to HK$45.5, with a turnover of HK$2.125,700.

According to the news, on July 21, Xinwei Medical announced the 2026 mid-term profit forecast. The company expects to achieve revenue of no less than 280 million yuan in the first half of 2026, with a year-on-year increase of more than 50.9%; net profit of not less than 60 million yuan; adjusted net profit of not less than 70 million yuan, an increase of at least 104.7% year on year, further improving profitability.

During the reporting period, the company continued to promote the development of the three core businesses of ischemic stroke, hemorrhagic stroke and vascular closure. The clinical approval and market penetration rate of core products continued to increase, driving steady growth in terminal demand. The increase in adjusted net profit was mainly due to an increase in the revenue contribution of high-margin products, which led to an increase in overall gross margin compared to the same period last year; and an increase in operating efficiency.